Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.59
- Piotroski Score 7.00
- Grade Neutral
- Symbol (NVS)
- Company Novartis AG
- Price $103.08
- Changes Percentage (-0.18%)
- Change -$0.19
- Day Low $102.46
- Day High $103.19
- Year High $120.92
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 09/24/2024
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 01/29/2025
- Fiscal Year End N/A
- Average Stock Price Target $120.00
- High Stock Price Target $121.00
- Low Stock Price Target $108.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $4.40
- Trailing P/E Ratio 23.94
- Forward P/E Ratio 23.94
- P/E Growth 23.94
- Net Income $14.85 B
Income Statement
Quarterly
Annual
Latest News of NVS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely?
Investing in unprofitable businesses can be profitable, but risky due to potential cash burn issues. Annovis Bio (NYSE: ANVS) had a short cash runway of 7 months in September 2024, with a cash burn of...
By Yahoo! Finance | 1 week ago -
Envista Holdings Corp (NVST) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...
Eric Hammes, CFO, discusses managing inventory reductions and improving working capital. He addresses Spark revenue deferrals and their impact, emphasizing lower impact in Q4 and a positive outlook fo...
By Yahoo! Finance | 3 weeks ago -
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
Novartis Ag (NVS) reported strong Q3 results with sales up 10% and core operating income up 20%. Key highlights included Kisqali's FDA approval and CHMP-positive opinion in early breast cancer, as wel...
By Yahoo! Finance | 3 weeks ago
